Fennec Pharmaceuticals Inc. (FENC)
NASDAQ: FENC · Real-Time Price · USD
10.52
+0.41 (4.06%)
Aug 5, 2026, 4:00 PM EDT - Market closed
Fennec Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 6 analysts polled by S&P Global, Fennec Pharmaceuticals stock has a consensus rating of "Strong Buy" and an average price target of $15.67. The average 1-year stock price forecast is 48.95% higher than the current stock price, while the lowest is $13 (+23.57%) and the highest is $18 (+71.10%).
Price Target: $15.67 (+48.95%)
Analyst Consensus: Strong Buy
Price Target
Chart* Price targets were last updated on May 22, 2026.
Analyst Ratings
The average analyst rating for Fennec Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 5 | 5 | 5 | 5 | 4 |
| Buy | 2 | 1 | 1 | 1 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 6 | 7 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Maxim Group | Maxim Group | Buy Maintains $15 | Buy | Maintains | $15 | +42.59% | May 22, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $13 → $16 | Buy | Reiterates | $13 → $16 | +52.09% | May 22, 2026 |
| Piper Sandler | Piper Sandler | Buy Reiterates $18 | Buy | Reiterates | $18 | +71.10% | May 15, 2026 |
Unknown Analyst Wedbush No rating | Wedbush | Buy Maintains $13 | Buy | Maintains | $13 | +23.57% | May 15, 2026 |
| Craig-Hallum | Craig-Hallum | Buy Maintains n/a | Buy | Maintains | n/a | n/a | Apr 22, 2026 |
Financial Forecast
Revenue This Year
69.83M
from 44.64M
Increased by 56.41%
Revenue Next Year
100.44M
from 69.83M
Increased by 43.85%
EPS This Year
0.30
from -0.28
EPS Next Year
0.89
from 0.30
Increased by 200.68%
EPS and Forward PE are based on non-GAAP adjusted numbers.